Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fenbendazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 8/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.66 |
| ▸ | HPGD | P15428 | 3/20 | 0.66 |
| ▸ | TP53 | P04637 | 2/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
| ▸ | KDR | P35968 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | ABL1 | P00519 | 2/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fenbendazole SCHEMBL8469702 | 1.00 | LMNA (1.00) | LMNACYP1A2MEN1KMT2ANR1I2 | |
| Fenbendazole SCHEMBL31076495 | 0.92 | LMNA (0.85) | LMNACYP1A2MEN1KMT2ANR1I2 | |
| SCHEMBL31197291 | 0.90 | LMNA (0.82) | LMNACYP1A2MEN1KMT2ANR1I2 | |
| SCHEMBL31197292 | 0.90 | LMNA (0.82) | LMNACYP1A2MEN1KMT2ANR1I2 | |
| Fenbendazole SCHEMBL31547342 | 0.90 | LMNA (0.82) | LMNACYP1A2MEN1KMT2ANR1I2 | |
| Fenbendazole SCHEMBL3988034 | 0.90 | LMNA (0.82) | LMNACYP1A2MEN1KMT2ANR1I2 | |
| Fenbendazole SCHEMBL166352 | 0.90 | LMNA (0.82) | LMNACYP1A2MEN1KMT2ANR1I2 | |
| Fenbendazole SCHEMBL31547327 | 0.90 | LMNA (0.82) | LMNACYP1A2MEN1KMT2ANR1I2 | |
| Fenbendazole SCHEMBL845544 | 0.90 | LMNA (0.81) | LMNACYP1A2MEN1KMT2ANR1I2 | |
| Fenbendazole SCHEMBL28228589 | 0.89 | LMNA (0.80) | LMNACYP1A2MEN1KMT2ANR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4586825-A1 | FEED AND METHODS FOR CONTROLLING INTESTINAL TRACT PARASITIC WORM INFECTIONS IN MAMMALS | In the Bowl Animal Health, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4429763-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | Yewsavin, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| WO-2024059803-A1 | FEED AND METHODS FOR CONTROLLING INTESTINAL TRACT PARASITIC WORM INFECTIONS IN MAMMALS | IN THE BOWL ANIMAL HEALTH, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | LMNA 1817/4885CYP1A2 1041/4885MEN1 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.